Newtyn Management, LLC Tcr2 Therapeutics Inc. Transaction History

Newtyn Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.0 - $1.62 $59,080 - $95,709	-59,080 Reduced 5.5%	1,015,920 $1.52 Million
Q4 2022 Feb 14, 2023	BUY	$0.83 - $1.44 $394,250 - $684,000	475,000 Added 79.17%	1,075,000 $1.08 Million
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $172,606 - $347,996	-92,799 Reduced 13.39%	600,000 $1.08 Million
Q2 2022 Aug 15, 2022	BUY	$2.11 - $2.94 $1.46 Million - $2.04 Million	692,799 New	692,799 $2.01 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.